Mythic Therapeutics Presents Positive Phase 1 Data for MYTX-011 in NSCLC

Mythic Therapeutics announced positive efficacy data from the Phase 1 KisMET-01 study of MYTX-011, a cMET-targeting antibody-drug conjugate (ADC), in ...
Home/KnloSights/Clinical Trial Updates/Mythic Therapeutics Presents Positive Phase 1 Data for MYTX-011 in NSCLC